Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q08334

UPID:
I10R2_HUMAN

ALTERNATIVE NAMES:
Cytokine receptor class-II member 4; Cytokine receptor family 2 member 4; Interleukin-10 receptor subunit 2

ALTERNATIVE UPACC:
Q08334; Q9BUU4

BACKGROUND:
The Interleukin-10 receptor subunit beta, recognized for its critical function in mediating the antiviral activity of cytokines IFNL2 and IFNL3, is integral to the immune response against viral pathogens. This receptor's activation triggers a cascade leading to antiviral state induction.

THERAPEUTIC SIGNIFICANCE:
Exploring the Interleukin-10 receptor subunit beta's function offers promising avenues for therapeutic intervention in autoimmune and inflammatory diseases, including the genetically linked Inflammatory bowel disease 25.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.